Stockreport

ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

ASLAN Pharmaceuticals Limited - American Depositary Shares  (ASLN) 
US:NASDAQ Investor Relations: ir.aslanpharma.com
PDF - ASLAN004 demonstrates early signs of efficacy in the low dose cohort of multiple ascending dose study - 3 patients completed 1 month of dosing and achieved average re [Read more]